AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35656851
Drug: Refill-based opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refill-based opioid prescription method (experimental arm)
Trial: 35656851
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (single prescription for all postoperative narcotics)
Trial: 32665040
Drug: Lopinavir (400mg)
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir (400mg) / Ritonavir (100mg) twice daily for 10 days
Trial: 32665040
Drug: Hydroxychloroquine (800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800mg on Day 1, followed by 400mg twice a day for 6 days)
Trial: 33628403
Drug: Lower limb
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower limb joint nursing and rehabilitation system based on intelligent medical treatment
Trial: 34075872
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing for respiratory tract diagnoses (RTDs)
Trial: 34075872
Drug: Family medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family medicine versus internal medicine
Trial: 38700630
Drug: 14-day bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day bismuth-containing quadruple therapy
Trial: 35636341
Drug: TPM (metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPM (metronomic oral cyclophosphamide + Trastuzumab + Pertuzumab)
Trial: 33750355
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) supplementation 400 μg/day from the 14th gestational week
Trial: 34032286
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of rEPO (loading dose 2000 IU, infusion at 520 IU/h) from 6 to 72 h post-asphyxia
Trial: 34032286
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline or 5000 IU rEPO, with repeated doses every 48 h for 5 days
Trial: 35778620
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment for 7 days
Trial: 33212205
Drug: Multicomponent behavioral
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent behavioral intervention program including fluid intake prescription and adaptive behavioral interventions (financial incentives, structured problem solving, automated adherence interventions)
Trial: 33028243
Drug: Integrated GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated GP care plus treatment as usual
Trial: 35398241
Drug: 3 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day Zataria multiflora extract
Trial: 35398241
Drug: 6 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg/day Zataria multiflora extract
Trial: 34486305
Drug: KCl 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCl 0.45 g/polybag + T. asperellum 30 g/polybag (K3)
Trial: 34486305
Drug: KCl 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCl 0.15 g/polybag + T. asperellum 50 g/polybag (K1)
Trial: 34486305
Drug: KCl 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCl 0.30 g/polybag + T. asperellum 40 g/polybag (K2)
Trial: 34486305
Drug: KCl 0.60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCl 0.60 g/polybag + T. asperellum 20 g/polybag (K4)
Trial: 34486305
Drug: KCl 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCl 0.75 g/polybag + T. asperellum 10 g/polybag (K5)
Trial: 35730664
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Trial: 35730664
Drug: Subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Trial: 34147090
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of infants with hemodynamically significant PDA (hsPDA)
Trial: 36093907
Drug: L-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (8 g/d for 7 days)
Trial: 35694030
Drug: Curcumin (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (4000 mg daily)
Trial: 34034690
Drug: ADVANCE intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVANCE intervention + substance use treatment as usual (TAU), n=54
Trial: 616191660
Drug: Compression Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression Therapy (CT)
Trial: 33960119
Drug: mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron 50 mg QD
Trial: 33960119
Drug: solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 5 mg QD
Trial: 34519141
Drug: Aerolizer® with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerolizer® with 200 µg salbutamol
Trial: 34519141
Drug: Handihaler® with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handihaler® with 200 µg salbutamol
Trial: 33948712
Drug: Lenvatinib (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (8 mg/day for < 60 kg; 12 mg/day for ≥ 60 kg)
Trial: 34780022
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (dapagliflozin 10 mg or empagliflozin 10 mg)
Trial: 34780022
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy
Trial: 34479930
Drug: Retrorectus mesh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrorectus mesh augmentation with lightweight polypropylene mesh
Trial: 36151932
Drug: 6-implant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-implant group
Trial: 33092415
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (GnRH-A)
Trial: 34604251
Drug: Huashibaidu granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huashibaidu granule 10 g twice daily
Trial: 33337109
Drug: Conventional energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional energy drink (ED1) containing carbohydrates and 3 mg·kg‐1 of caffeine
Trial: 33337109
Drug: Sugar-free energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free energy drink (ED2) containing 3 mg·kg‐1 of caffeine
Trial: 32429429
Drug: Cod residual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod residual protein (Cod-RP) 8.1 g/day for eight weeks
Trial: 33856613
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (0-120 IU of NovoLog) with exercise
Trial: 33856613
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (0-120 IU of NovoLog) with sitting control
Trial: 32591295
Drug: HF nurse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HF nurse titration
Trial: 32591295
Drug: HF cardiologist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF cardiologist titration
Trial: 32894967
Drug: Polypill (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg)
Trial: 32569090
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITMO)
Trial: 34843940
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg/body) administered every 2 weeks for up to 52 cycles
Trial: 34388561
Drug: SSRIs alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs alone (drug group)
Trial: 33096986
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect modeling methods
Trial: 33096986
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment regime methods
Trial: 36457360
Drug: Video-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based cognitive behavioral therapy (CBT), 10 sessions over 12 weeks with a licensed clinical psychologist, using iPads via Apple FaceTime.
Trial: 32216621
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive hypnotherapy (8 sessions, weekly)
Trial: 33127212
Drug: Dexamethasone iontophoresis
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone iontophoresis (1 mg dexamethasone per 1 g administered under the active electrode, intensity of 0.1–0.2 mA/cm2 for ten days)
Trial: 35321938
Drug: Over-the-scope-clips (OTSC)
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-scope-clips (OTSC) therapy
Trial: 35321938
Drug: Standard endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard endoscopic treatment
Trial: 33514384
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil (25 g/day)
Trial: 33514384
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (25 g/day)
Trial: 33514384
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (25 g/day)
Trial: 34563236
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (DA) treatment
Trial: 32390545
Drug: Usual Treatment
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Treatment (Control)
Trial: 33050900
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks
Trial: 35780702
Drug: Delivered daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered daily dinner tray for 6 months with assistance during meals
Trial: 35232755
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase (IVT) + endovascular treatment (EVT)
Trial: 34314727
Drug: Agent drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent drug coated balloon (DCB)
Trial: 36411659
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement based on S-adenosyl methionine (SAMe, 200 mg/day) and probiotics (Lactobacillus helveticus Rosell®‐52, Bifidobacterium longum Rosell®‐175, 3 × 10^9 CFU/day)
Trial: 34488361
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (internal anal sphincterotomy)
Trial: 32916609
Drug: Semaglutide 2.4
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 2.4 mg subcutaneously once weekly
Trial: 35266243
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.2 g/kg
Trial: 35266243
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.4 g/kg
Trial: 33483355
Drug: 8-week educational
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week educational programme on top of usual treatment
Trial: 34581424
Drug: QFR-guided complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QFR-guided complete revascularization (QFR-G-CR)
Trial: 33692183
Drug: Scheduled 6-hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled 6-hourly IV acetaminophen for 48 hours post-cardiac surgery
Trial: 35881907
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg before PCI and 0.5 mg daily after until discharge)
Trial: 35803757
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenously after induction of anaesthesia
Trial: 35202353
Drug: Standard 6-month
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6-month regimen for tuberculosis treatment
Trial: 34579763
Drug: Hishi extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hishi extract (100 mg/day)
Trial: 34219000
Drug: Atezolizumab 840
RxNorm normalized name: atezolizumab 840 MG in 14 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 840 mg with paclitaxel 90 mg/m2
Trial: 34219000
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with paclitaxel 90 mg/m2
Trial: 33787411
Drug: Late endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late endovascular treatment in patients with clinical‐ASPECTS mismatch (NIHSS ≥ 10 and ASPECTS ≥ 7, or NIHSS ≥ 20 and ASPECTS ≥ 5)
Trial: 33787411
Drug: Late endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late endovascular treatment in patients without clinical‐ASPECTS mismatch
Trial: 32336008
Drug: Vandetanib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (100 mg once daily)
Trial: 36175936
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate Ringer's solution (BRS)
Trial: 36175936
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate Ringer's solution (control group)
Trial: 33896751
Drug: Transarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial infusion chemotherapy plus microsphere embolization for gastroesophageal cancer and transarterial chemoembolization for hepatic metastasis
Trial: 33896751
Drug: Transarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial infusion chemotherapy for gastroesophageal cancer and transarterial chemoembolization for hepatic metastasis
Trial: 33896751
Drug: Transarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial infusion chemotherapy plus microsphere embolization
Trial: 34639295
Drug: Chuna manual
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chuna manual therapy (CMT) plus usual Korean traditional medicine care for three weeks (6-11 sessions)
Trial: 34639295
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including acupuncture, cupping, herbal medicine, moxibustion, and traditional physiotherapy
Trial: 34639295
Drug: Chuna manual
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chuna manual therapy (CMT) plus usual Korean traditional medicine care
Trial: 33167779
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) using support vector machines (SVM) and convolutional neural networks (CNN) trained on ventricular monophasic action potentials (MAPs) to predict sustained ventricular tachycardia/ventricular fibrillation (VT/VF) and mortality.
Trial: 33167779
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) using support vector machines (SVM) and convolutional neural networks (CNN) trained on ventricular monophasic action potentials (MAPs) to predict mortality.
Trial: 36335918
Drug: Initial invasive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial invasive strategy added to guideline-directed medical therapy
Trial: 33409923
Drug: Zinc, Vitamin
RxNorm normalized name: Vita-Zinc, Vitamin B Complex with C and Zinc oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc, Vitamin A, and Magnesium supplementation (30 mg zinc gluconate capsule per day, 250 mg magnesium oxide tablet per day, 25,000 IU vitamin A capsule twice/week for 10 weeks)
Trial: 33409923
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo capsules and tablets for 10 weeks)
Trial: 34648009
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (loading dose of 0.5 μg/kg over 15 minutes followed by a maintenance dose of 0.2 μg/kg per hour)
Trial: 32511775
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. reuteri lozenges
Trial: 35268094
Drug: Medium-Chain Triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-Chain Triglycerides (MCTs) - 2 g daily for two weeks
Trial: 35536382
Drug: Celery seed
RxNorm normalized name: CELERY SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celery seed extract (1.34 g extract per day)
Trial: 32365242
Drug: Clobetasol cream
RxNorm normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol cream
Trial: 35110003
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) - single dose of aluminum gallium arsenide (GaAlAs) laser irradiation (808 nm; 350 milliwatts; 3.5 joule/point) with placebo medication.
Trial: 35110003
Drug: Paracetamol–caffeine tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol–caffeine tablets (3 times daily for the first couple of days after separator insertion, and as needed for the rest of the week) with placebo LED light.
Trial: 32476089
Drug: Simple Oral
RxNorm normalized name: Simple Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Oral Exercise (SOE)
Trial: 34512931
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride injection combined with dexmedetomidine
Trial: 34512931
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride injection
Trial: 36206793
Drug: Antibiotic review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic review kit intervention
Trial: 32351183
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) treatment with a high level of CBD to low level of THC ratio
Trial: 32351183
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological treatment
Trial: 34118059
Drug: ≥1000 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥1000 IU/day vitamin D3 (pooled higher doses)
Trial: 32316978
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell vaccines (DCV)
Trial: 32316978
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor cell vaccines (TCV)
Trial: 36321411
Drug: Active titration
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active titration
Trial: 36321411
Drug: Usual titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual titration
Trial: 35060398
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for postpartum depression delivered by public health nurses plus treatment as usual (TAU)
Trial: 35701773
Drug: Cinnamaldehyde mucoadhesive
RxNorm normalized name: Cinnamaldehyde
DrugBank: Cinnamaldehyde (DB14184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamaldehyde mucoadhesive patches
Trial: 35701773
Drug: Placebo mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mucoadhesive patches